Novel perspectives of testosterone therapy in men with functional hypogonadism: traversing the gaps of knowledge

References

• Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi: 10.1210/jc.2018-00229.
   PubMed Web of Science ®Google Scholar
• Grossmann M, Jones TH. Functional hypogonadism in middle-aged and older men: testosterone treatment or not? Eur J Endocrinol. 2021;185(3):D1–D9. doi: 10.1530/EJE-21-0362.
   PubMed Web of Science ®Google Scholar
• Wu FCW, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–135. doi: 10.1056/NEJMoa0911101.
   PubMed Web of Science ®Google Scholar
• Calderón B, Gómez-Martín JM, Vega-Piñero B, et al. Prevalence of male secondary hypogonadism in moderate to severe obesity and its relationship with insulin resistance and excess body weight. Andrology. 2016;4(1):62–67. doi: 10.1111/andr.12135.
   PubMed Web of Science ®Google Scholar
• Schipf S, Haring R, Friedrich N, et al. Low total testosterone is associated with increased risk of incident type 2 diabetes mellitus in men: results from the study of health in pomerania (SHIP). Aging Male. 2011;14(3):168–175. doi: 10.3109/13685538.2010.524955.
   PubMed Web of Science ®Google Scholar
• Haring R, Völzke H, Steveling A, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20–79. Eur Heart J. 2010;31(12):1494–1501. doi: 10.1093/eurheartj/ehq009.
   PubMed Web of Science ®Google Scholar
• Isidori AM, Aversa A, Calogero A, et al. Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian society of andrology and sexual medicine (SIAMS) and the Italian society of endocrinology (SIE). J Endocrinol Invest. 2022;45(12):2385–2403. doi: 10.1007/s40618-022-01859-7.
   PubMed Web of Science ®Google Scholar
• Corona G, Torres LO, Maggi M. Testosterone therapy: what we have learned from trials. J Sex Med. 2020;17(3):447–460. doi: 10.1016/j.jsxm.2019.11.270.
   PubMed Web of Science ®Google Scholar
• Corona G, Goulis DG, Huhtaniemi I, et al. European academy of andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males. Andrology. 2020;8(5):970–987. doi: 10.1111/andr.12770.
   PubMed Web of Science ®Google Scholar
• Wittert G, Bracken K, Robledo KP, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021;9(1):32–45. doi: 10.1016/S2213-8587(20)30367-3.
   PubMed Web of Science ®Google Scholar
• Wittert G, Grossmann M. Obesity, type 2 diabetes, and testosterone in ageing men. Rev Endocr Metab Disord. 2022;23(6):1233–1242. doi: 10.1007/s11154-022-09746-5.
   PubMed Web of Science ®Google Scholar
• Grossmann M, Matsumoto AM. A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. J Clin Endocrinol Metab. 2017;102(3):1067–1075. doi: 10.1210/jc.2016-3580.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Morelli A, et al. Treatment of functional hypogonadism besides pharmacological substitution. World J Mens Health. 2020;38(3):256–270. doi: 10.5534/wjmh.190061.
   PubMedGoogle Scholar
• Bellastella G, Menafra D, Puliani G, et al. How much does obesity affect the male reproductive function? Int J Obes Suppl. 2019;9(1):50–64. doi: 10.1038/s41367-019-0008-2.
   PubMedGoogle Scholar
• Louters M, Pearlman M, Solsrud E, et al. Functional hypogonadism among patients with obesity, diabetes, and metabolic syndrome. Int J Impot Res. 2021;34(7):714–720. [Internet]. doi: 10.1038/s41443-021-00496-7.
   PubMed Web of Science ®Google Scholar
• Grossmann M, Ng Tang Fui M, Cheung AS. Late-onset hypogonadism: metabolic impact. Andrology. 2019;8(6):1519–1529. doi: 10.1111/andr.12705.
   PubMed Web of Science ®Google Scholar
• Yeap BB, Knuiman MW, Divitini ML, et al. Differential associations of testosterone, dihydrotestosterone and oestradiol with physical, metabolic and health-related factors in community-dwelling men aged 17-97 years from the Busselton health survey. Clin Endocrinol. 2014;81(1):100–108. doi: 10.1111/cen.12407.
   PubMed Web of Science ®Google Scholar
• Srinath R, Hill Golden S, Carson KA, et al. Endogenous testosterone and its relationship to preclinical and clinical measures of cardiovascular disease in the atherosclerosis risk in communities study. J Clin Endocrinol Metab. 2015;100(4):1602–1608. doi: 10.1210/jc.2014-3934.
   PubMed Web of Science ®Google Scholar
• Ding EL, Song Y, Malik VS, et al. Sex differences of endogenous sex hormones and risk of type 2 DiabetesA systematic review and meta-analysis. JAMA. 2006;295(11):1288–1299. doi: 10.1001/jama.295.11.1288.
   PubMed Web of Science ®Google Scholar
• Yeap BB, Wittert GA. Testosterone, diabetes risk, and diabetes prevention in men. Endocrinol Metab Clin North Am. 2022;51(1):157–172. doi: 10.1016/j.ecl.2021.11.004.
   PubMed Web of Science ®Google Scholar
• Hall SA, Esche GR, Araujo AB, et al. Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. J Clin Endocrinol Metab. 2008;93(10):3870–3877. doi: 10.1210/jc.2008-0021.
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91(11):4335–4343. doi: 10.1210/jc.2006-0401.
   PubMed Web of Science ®Google Scholar
• Jackson JA, Riggs MW, Spiekerman AM. Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Am J Med Sci. 1992;304(1):4–8. doi: 10.1097/00000441-199207000-00003.
   PubMed Web of Science ®Google Scholar
• Heinemann LAJ, Saad F, Zimmermann T, et al. The aging males’ symptoms (AMS) scale: update and compilation of international versions. Health Qual Life Outcomes. 2003;1(1):15. doi: 10.1186/1477-7525-1-15.
   PubMedGoogle Scholar
• Dandona P, Rosenberg MT. A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract. 2010;64(6):682–696. doi: 10.1111/j.1742-1241.2010.02355.x.
   PubMed Web of Science ®Google Scholar
• Martits A, Costa E, Nardi A, et al. Late-onset hypogonadism or ADAM: diagnosis. Rev Assoc Med Bras. 2014;60(4):286–294. doi: 10.1590/1806-9282.60.04.003.
   PubMed Web of Science ®Google Scholar
• Dhindsa S, Ghanim H, Batra M, et al. Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Diabetes Care. 2016;39(1):82–91. doi: 10.2337/dc15-1518.
   PubMed Web of Science ®Google Scholar
• Groti K, Žuran I, Antonič B, et al. The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male. 2018;21(3):158–169. doi: 10.1080/13685538.2018.1468429.
   PubMed Web of Science ®Google Scholar
• Groti Antonič K, Antonič B, Žuran I, et al. Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male. 2020 (5):1442–1454. doi: 10.1080/13685538.2020.1793132.
   PubMed Web of Science ®Google Scholar
• Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899–906. doi: 10.1530/eje.1.02166.
   PubMed Web of Science ®Google Scholar
• Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in Middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med. 2010;7(10):3495–3503. doi: 10.1111/j.1743-6109.2010.01931.x.
   PubMed Web of Science ®Google Scholar
• Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34(4):828–837. doi: 10.2337/dc10-1233.
   PubMed Web of Science ®Google Scholar
• Hackett G, Cole N, Bhartia M, et al. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med. 2014;11(3):840–856. doi: 10.1111/jsm.12404.
   PubMed Web of Science ®Google Scholar
• Kalinchenko SY, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double‐blinded placebo‐controlled moscow study. Clin Endocrinol. 2010;73(5):602–612. doi: 10.1111/j.1365-2265.2010.03845.x.
   PubMed Web of Science ®Google Scholar
• Gianatti EJ, Dupuis P, Hoermann R, et al. Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2014;37(8):2098–2107. doi: 10.2337/dc13-2845.
   PubMed Web of Science ®Google Scholar
• Heufelder AE, Saad F, Bunck MC, et al. Fifty‐two week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009;30(6):726–733. doi: 10.2164/jandrol.108.007005.
   PubMedGoogle Scholar
• Skinner JW, Otzel DM, Bowser A, et al. Muscular responses to testosterone replacement vary by administration route: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2018;9(3):465–481. doi: 10.1002/jcsm.12291.
   PubMed Web of Science ®Google Scholar
• Corona G, Giagulli VA, Maseroli E, et al. Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest. 2016;39(9):967–981. doi: 10.1007/s40618-016-0480-2.
   PubMed Web of Science ®Google Scholar
• Dandona P, Dhindsa S, Ghanim H, et al. Mechanisms underlying the metabolic actions of testosterone in humans: a narrative review. Diabetes Obes Metab. 2021;23(1):18–28. doi: 10.1111/dom.14206.
   PubMed Web of Science ®Google Scholar
• Day EA, Ford RJ, Steinberg GR. AMPK as a therapeutic target for treating metabolic diseases. Trends Endocrinol Metab. 2017;28(8):545–560. doi: 10.1016/j.tem.2017.05.004.
   PubMed Web of Science ®Google Scholar
• Ghanim H, Dhindsa S, Batra M, et al. Testosterone increases the expression and phosphorylation of AMP kinase α in men with hypogonadism and type 2 diabetes. J Clin Endocrinol Metab. 2020;105(4):1169–1175. doi: 10.1210/clinem/dgz288.
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89(7):3313–3318. doi: 10.1210/jc.2003-031069.
   PubMed Web of Science ®Google Scholar
• Mohamad NV, Wong SK, Wan Hasan WN, et al. The relationship between circulating testosterone and inflammatory cytokines in men. Aging Male. 2019;22(2):129–140. doi: 10.1080/13685538.2018.1482487.
   PubMed Web of Science ®Google Scholar
• Yassin A, Haider A, Haider KS, et al. Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: eight-year data from a registry study. Diabetes Care. 2019;42(6):1104–1111. doi: 10.2337/dc18-2388.
   PubMed Web of Science ®Google Scholar
• Grams J, Garvey WT. Weight loss and the prevention and treatment of type 2 diabetes using lifestyle therapy, pharmacotherapy, and bariatric surgery: mechanisms of action. Curr Obes Rep. 2015;4(2):287–302. doi: 10.1007/s13679-015-0155-x.
   PubMed Web of Science ®Google Scholar
• Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity. 2014;22(1):5–13.
   PubMed Web of Science ®Google Scholar
• Srikanthan P, Karlamangla AS. Relative muscle mass is inversely associated with insulin resistance and prediabetes. Findings from the third national health and nutrition examination survey. J Clin Endocrinol Metab. 2011;96(9):2898–2903. doi: 10.1210/jc.2011-0435.
   PubMed Web of Science ®Google Scholar
• Saad F, Doros G, Haider KS, et al. Differential effects of 11 years of long-term injectable testosterone undecanoate therapy on anthropometric and metabolic parameters in hypogonadal men with normal weight, overweight and obesity in comparison with untreated controls: real-world data from a controlled registry study. Int J Obes. 2020;44(6):1264–1278. doi: 10.1038/s41366-019-0517-7.
   Web of Science ®Google Scholar
• Antonic KG. Effects of testosterone therapy on morphology and grade of NAFLD in obese men with functional hypogonadism and type 2 diabetes. Presented at Society of Endocrinology BES, Harrogate, UK. Endocrine Abstracts 73 PEP7.1. doi: 10.1530/endoabs.73.PEP7.1.
   Google Scholar
• Yassin AA, Alwani M, Talib R, et al. Long-term testosterone therapy improves liver parameters and steatosis in hypogonadal men: a prospective controlled registry study. Aging Male. 2020;23(5):1553–1563. doi: 10.1080/13685538.2020.1867094.
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Bhasin S, Cunningham GR, et al. Lessons from the testosterone trials. Endocr Rev. 2018;39(3):369–386. doi: 10.1210/er.2017-00234.
   PubMed Web of Science ®Google Scholar
• Emmelot-Vonk MH, Verhaar HJJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299(1):39–52. doi: 10.1001/jama.2007.51.
   PubMed Web of Science ®Google Scholar
• Haider KS, Haider A, Saad F, et al. Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study. Diabetes Obes Metab. 2020;22(11):2055–2068. doi: 10.1111/dom.14122.
   PubMed Web of Science ®Google Scholar
• Rochira V, Antonio L, Vanderschueren D. EAA clinical guideline on management of bone health in the andrological outpatient clinic. Andrology. 2018;6(2):272–285. doi: 10.1111/andr.12470.
   PubMed Web of Science ®Google Scholar
• Vidal M, Thibodaux RJ, Neira LFV, et al. Osteoporosis: a clinical and pharmacological update. Clin Rheumatol. 2019;38(2):385–395. doi: 10.1007/s10067-018-4370-1.
   PubMed Web of Science ®Google Scholar
• Isidori AM, Balercia G, Calogero AE, et al. Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. J Endocrinol Invest. 2015;38(1):103–112. doi: 10.1007/s40618-014-0155-9.
   PubMed Web of Science ®Google Scholar
• Laitinen EM, Hero M, Vaaralahti K, et al. Bone mineral density, body composition and bone turnover in patients with congenital hypogonadotropic hypogonadism. Int J Androl. 2012;35(4):534–540. doi: 10.1111/j.1365-2605.2011.01237.x.
   PubMedGoogle Scholar
• Shigehara K, Konaka H, Koh E, et al. Effects of testosterone replacement therapy on hypogonadal men with osteopenia or osteoporosis: a subanalysis of a prospective randomized controlled study in Japan (EARTH study). Aging Male. 2017;20(3):139–145. doi: 10.1080/13685538.2017.1303829.
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999;84(6):1966–1972. doi: 10.1210/jc.84.6.1966.
   PubMed Web of Science ®Google Scholar
• Ng Tang Fui M, Hoermann R, Bracken K, et al. Effect of testosterone treatment on bone microarchitecture and bone mineral density in men: a 2-year RCT. J Clin Endocrinol Metab. 2021;106(8):e3143–58–e3158. doi: 10.1210/clinem/dgab149.
   Web of Science ®Google Scholar
• Herrmann M, Engelke K, Ebert R, et al. Interactions between muscle and bone-where physics meets biology. Biomolecules. 2020;10(3):432. doi: 10.3390/biom10030432.
   PubMed Web of Science ®Google Scholar
• Jayasena CN, Anderson RA, Llahana S, et al. Society for endocrinology guidelines for testosterone replacement therapy in male hypogonadism. Clin Endocrinol. 2022;96(2):200–219. doi: 10.1111/cen.14633.
   PubMed Web of Science ®Google Scholar
• Welch BJ, Denke MA, Kermani A, et al. Comparison of testosterone, alendronate, and a combination of both therapies in men with low bone mineral density. J Investig Med. 2007;55(4):168–173. doi: 10.2310/6650.2007.06047.
   PubMed Web of Science ®Google Scholar
• Greco EA, Pietschmann P, Migliaccio S. Osteoporosis and sarcopenia increase frailty syndrome in the elderly. Front Endocrinol. 2019;10:255. doi: 10.3389/fendo.2019.00255.
   PubMed Web of Science ®Google Scholar
• Rochira V. Late-onset hypogonadism: bone health. Andrology. 2020;8(6):1539–1550. doi: 10.1111/andr.12827.
   PubMed Web of Science ®Google Scholar
• Khripun I, Vorobyev S, Belousov I, et al. Influence of testosterone substitution on glycemic control and endothelial markers in men with newly diagnosed functional hypogonadism and type 2 diabetes mellitus: a randomized controlled trial. Aging Male. 2019;22(4):241–249. doi: 10.1080/13685538.2018.1506918.
   PubMed Web of Science ®Google Scholar
• Charbit B, Christin-Maître S, Démolis JL, et al. Effects of testosterone on ventricular repolarization in hypogonadic men. Am J Cardiol. 2009;103(6):887–890. doi: 10.1016/j.amjcard.2008.11.041.
   PubMed Web of Science ®Google Scholar
• Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis. 2009;207(2):318–327. doi: 10.1016/j.atherosclerosis.2009.04.016.
   PubMed Web of Science ®Google Scholar
• Cairrão E, Alvarez E, Santos-Silva AJ, et al. Potassium channels are involved in testosterone-induced vasorelaxation of human umbilical artery. Naunyn Schmiedebergs Arch Pharmacol. 2008;376(5):375–383. doi: 10.1007/s00210-007-0213-3.
   PubMed Web of Science ®Google Scholar
• Jones RD, English KM, Pugh PJ, et al. Pulmonary vasodilatory action of testosterone: evidence of a calcium antagonistic action. J Cardiovasc Pharmacol. 2002;39(6):814–823. doi: 10.1097/00005344-200206000-00006.
   PubMed Web of Science ®Google Scholar
• Sharma R, Oni OA, Gupta K, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36(40):2706–2715. doi: 10.1093/eurheartj/ehv346.
   PubMed Web of Science ®Google Scholar
• Mäkinen J, Järvisalo MJ, Pöllänen P, et al. Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol. 2005;45(10):1603–1608. doi: 10.1016/j.jacc.2005.01.052.
   PubMed Web of Science ®Google Scholar
• Mathur A, Malkin C, Saeed B, et al. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol. 2009;161(3):443–449. doi: 10.1530/EJE-09-0092.
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Vorona E, Wenk M, et al. Testosterone administration decreases carotid artery intima media thickness as a marker of impaired vascular integrity in middle-aged overweight men. J Mens Health. 2009;6(3):243–243. doi: 10.1016/j.jomh.2009.08.059.
   Web of Science ®Google Scholar
• Ajayi AAL, Halushka PV. Castration reduces platelet thromboxane A2 receptor density and aggregability. QJM. 2005;98(5):349–356. doi: 10.1093/qjmed/hci054.
   PubMed Web of Science ®Google Scholar
• Webb CM, McNeill JG, Hayward CS, et al. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation. 1999;100(16):1690–1696. doi: 10.1161/01.cir.100.16.1690.
   PubMed Web of Science ®Google Scholar
• Corona G, Dicuio M, Rastrelli G, et al. Testosterone treatment and cardiovascular and venous thromboembolism risk: what is “new”. J Investig Med. 2017;65(6):964–973. doi: 10.1136/jim-2017-000411.
   PubMed Web of Science ®Google Scholar
• Ayele HT, Brunetti VC, Renoux C, et al. Testosterone replacement therapy and the risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials. Thromb Res. 2021;199:123–131. doi: 10.1016/j.thromres.2020.12.029.
   PubMed Web of Science ®Google Scholar
• Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLOS One. 2014;9(1):e85805. doi: 10.1371/journal.pone.0085805.
   PubMed Web of Science ®Google Scholar
• Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829–1836. doi: 10.1001/jama.2013.280386.
   PubMed Web of Science ®Google Scholar
• Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109–122. doi: 10.1056/NEJMoa1000485.
   PubMed Web of Science ®Google Scholar
• Shores MM, Smith NL, Forsberg CW, et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97(6):2050–2058. doi: 10.1210/jc.2011-2591.
   PubMed Web of Science ®Google Scholar
• Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169(6):725–733. doi: 10.1530/EJE-13-0321.
   PubMed Web of Science ®Google Scholar
• Basaria S, Harman S, Travison TG, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA. 2015;314(6):570–581. doi: 10.1001/jama.2015.8881.
   PubMed Web of Science ®Google Scholar
• Hudson J, Cruickshank M, Quinton R, et al. Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis. Lancet Healthy Longev. 2022;3(6):e381–93–e393. doi: 10.1016/S2666-7568(22)00096-4.
   Google Scholar
• Bhasin S, Lincoff AM, Basaria S, et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. Am Heart J. 2022;245:41–50. doi: 10.1016/j.ahj.2021.11.016.
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107–117. doi: 10.1056/NEJMoa2215025.
   PubMed Web of Science ®Google Scholar
• Pencina KM, Travison TG, Cunningham GR, et al. Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. J Clin Endocrinol Metab. 2023:dgad484. doi: 10.1210/clinem/dgad484.
   PubMed Web of Science ®Google Scholar